HEL 92.1.7
Export
erythroleukemia cell line
Cell Type:
Erythroblast
Tissue Origin:
blood
Species:
human
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cell Characteristics:
Suspension
Transfection Information
Lonza Optimized Protocol
Optimization Guideline
Filter:
Any Substrate
Any Platform
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols
or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our
optimization strategy
to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol
Kit
Program
Cells
Efficiency
Viable Cells
Substrate
Format
Platform
SF
DC-102
4e5
66%
64% ±3
Plasmid (general)
0.6 µg
20 µl
4D X-Unit
SF
DC-102
2e6
68%
54% ±1
Plasmid (general)
3 µg
100 µl
4D X-Unit
V
X-005
4e6
88%
66%
Plasmid (general)
2 µg
100 µl
I/II/2b
V
Y-013
4e6
94%
39%
Plasmid (general)
2 µg
100 µl
I/II/2b
V
X-005
5e6
69%
91%
Plasmid (general)
2 µg
100 µl
I/II/2b
V
T-020
5e6
65%
85%
Plasmid (general)
2 µg
100 µl
I/II/2b
Citations
PKCepsilon controls protection against TRAIL in erythroid progenitors
Categories:
Transfection
Authors:
Mirandola P, Gobbi G, Ponti C, Sponzilli I, Cocco L and Vitale M
In:
Blood (2006) 107(2): 508-513